Actinium Pharmaceuticals (NYSEAM:ATNM) - Hisse Senedi Fiyatı, Haberler ve Analizler

ATNM Stoklara Genel Bakış

ATNM temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 62.6% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 0.3% oranında düşmesi öngörülüyor

Geliri 1 milyon ABD dolarından az ( $81K )

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Actinium Pharmaceuticals, Inc. Rakipler

vTv Therapeutics

NasdaqCM:VTVT

US$37.0m

Entera Bio

NasdaqCM:ENTX

US$58.6m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Shattuck Labs

NasdaqGS:STTK

US$48.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Actinium Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.45
52 Haftanın En Yüksek Seviyesi	US$10.24
52 Haftanın En Düşük Seviyesi	US$1.33
Beta	0.15
11 Aylık Değişim	-13.69%
3 Aylık Değişim	-27.14%
1 Yıllık Değişim	-66.04%
33 Yıllık Değişim	-79.26%
5 Yıllık Değişim	-83.08%
Halka arzdan bu yana değişim	-98.39%

Son Haberler & Güncellemeler

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Hissedar Getirileri

	ATNM	US Biotechs	US Pazar
7D	2.1%	4.0%	2.2%
1Y	-66.0%	18.3%	32.6%

Getiri vs. Endüstri: ATNM geçen yıl % 18.3 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ATNM geçen yıl % 32.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ATNM's price volatile compared to industry and market?
ATNM volatility
ATNM Average Weekly Movement	9.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ATNM son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ATNM 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 10% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	37	Sandesh Seth	www.actiniumpharma.com

Actinium Pharmaceuticals, Inc. mevcut onkoloji tedavilerinde başarısız olan kişiler için sonuçları iyileştirmeyi amaçlayan antikor radyasyon konjugatları ve diğer hedefli radyoterapiler geliştirmektedir. Iomab-B, nükseden ve refrakter akut miyeloid lösemi (r/r AML) hastalarında kemik iliği nakli öncesinde bir indüksiyon ve kondisyonlama ajanıdır. Şirket, r/r AML hastalarında potansiyel aktivite gösteren terapötik bir ajan olan ürün adayı Actimab-A için geliştirmesini ilerletmeye odaklanmaktadır.

Actinium Pharmaceuticals, Inc. Temel Bilgiler Özeti

Actinium Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ATNM temel i̇stati̇sti̇kler
Piyasa değeri	US$45.23m
Kazançlar(TTM)	-US$40.91m
Gelir(TTM)	US$81.00k

558.4x

P/S Oranı

-1.1x

F/K Oranı

ATNM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ATNM gelir tablosu (TTM)
Gelir	US$81.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$81.00k
Diğer Giderler	US$41.00m
Kazançlar	-US$40.91m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.31
Brüt Marj	100.00%
Net Kâr Marjı	-50,512.35%
Borç/Özkaynak Oranı	0%

ATNM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ATNM Stoklara Genel Bakış

Ödüller

Risk Analizi

Actinium Pharmaceuticals, Inc. Rakipler

NasdaqCM:VTVT

US$37.0m

NasdaqCM:ENTX

US$58.6m

NasdaqGS:FIXX

US$54.3m

NasdaqGS:STTK

US$48.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Recent updates

New major risk - Revenue and earnings growth

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023